Clinical Guideline: TB Screening for Targeted and Biologic Agents: Prescribing including Anti-Tumour Necrosis Factor Drugs, Imperial College Healthcare NHS Trust, September 2020.

has been cited by the following article:

• TITLE: Chronic Spontaneous Urticaria on Omalizumab Therapy and Latent Tuberculosis Infection: A New Case Report

  AUTHORS: Waqas S. Abdulwahhab, Fatima M. Al Qaydi

  KEYWORDS: Chronic Spontaneous Urticaria, Latent Tuberculosis, Omalizumab, QuantiFERON-TB Test

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.13 No.1, March 15, 2023

  ABSTRACT: Background: Chronic Spontaneous urticarial (CSU) is a common dermatological problem characterized by recurrent pruritic or burning wheals last less than 24 hours and treated by many modalities of therapy including systemic antihistamines and in refractory cases with Omalizumab anti-IgE antibody biological injection. Latent tuberculosis infection (LTBI) is diagnosed based on a positive tuberculin skin test or QuantiFERON-TB test without evidence of active tuberculosis. Aim: To document a new case report of a patient with a history of CSU and latent tuberculosis on Omalizumab therapy during Isoniazid (INH) prophylaxis. Case Report: A-53-year-old woman with a history of CSU and newly identified LTBI who have been treated with INH monotherapy before starting Omalizumab injection followed up over 24 weeks course of therapy for any sign of tuberculosis reinfection. Conclusion: Omalizumab injection was used effectively for the treatment of CSU in a patient with latent tuberculosis infection with minimal risk of tuberculosis reactivation.